MEP including Acoustic Consultant/BSL3 Laboratory - Full and complete service for the duration of the project life cycle Validation Centre
Estimated value
£91k
Awarded value
£91k
Suppliers
1
Lots
1
Published
05 Jul 2021
Description
Medicines Discovery Catapult (MDC) is a national facility for collaborative R&D exploring and developing new approaches to the discovery and proof of well targeted medicines, diagnostics and biomarkers. Funded by Innovate UK, an agency of the UK government, MDC are an independent not-for-profit company bringing together a fragmented UK sector of industry, academia, charities, technologists, services, finance companies, SMEs and start-ups who together can turn good science into new, high value products. By sharing problems, rare expertise and assets we support the growth of this new community through a time of radical business and national change. Capitalising on the success of the Lighthouse Lab to create a new BSL3 facility for innovative diagnostics, biomarkers and complex medicines and develop the UK's onshore diagnostic capability and capacity and the associated supply chain. The project will create a national facility for testing and validation of new diagnostics, biomarkers and innovative therapeutics for disease. The Validation Centre of Excellence will enable innovators to set up new companies with confidence, driving regional growth in high-value jobs and a sector of urgent national and global need.
Scope
- Reference
- MEDDISC001-DN554695-28712316
- Total value
- £91,000 excluding VAT
- Commercial tool
- Standalone contract
- Contract dates
- 16 Jun 2021 to 29 Jun 2022
- CPV classifications
- 45000000 71000000
- Particular suitability
- Small and medium-sized enterprises (SME)
Submission & procedure
- Submission deadline
- 30 Apr 2021, 11:00 am
Award details
Awarded supplier(s), contract period and value as published in the award notice.
Awarded value
£91k
Award date
15 Jun 2021
Contract start
16 Jun 2021
Contract end
29 Jun 2022